MétaCan
Menu
← Back to cohort
Record W7093123001

C003 | MODELING LONG-TERM PROGRESSION-FREE SURVIVAL IN TRANSPLANT-ELIGIBLE AND TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE

2025· article· en· W7093123001 on OpenAlexaff

Bibliographic record

VenueDOAJ (DOAJ: Directory of Open Access Journals) · 2025
Typearticle
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsHotel Dieu HospitalUniversity of Calgary
Fundersnot available
KeywordsCohortPopulationMultiple myelomaRandomized controlled trialOverall survivalDexamethasone
DOInot available

Abstract

fetched live from OpenAlex

Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) plus DR maintenance showed superior efficacy to VRd with R maintenance in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the PERSEUS trial. Similarly, the CEPHEUS trial showed superiority of DVRd vs VRd in transplant-ineligible (TIE) or transplant-deferred pts with NDMM. In the DVRd arms, median progression-free survival (PFS) was not reached (NR) at median follow-up of 47.5 months (mo; PERSEUS) and 58.7 mo (CEPHEUS); in the VRd arms, median PFS was NR in PERSEUS and was 52.6 mo in CEPHEUS. This analysis aimed to extrapolate PFS data from PERSEUS (TE) and CEPHEUS (TIE) to estimate long-term outcomes of frontline DVRd to help inform clinical decision making. Per UK NICE guidance on survival data extrapolation, 7 distributions were fitted to model PFS: exponential, Weibull, gamma, Gompertz, log-logistic, log-normal, and generalized gamma. Individual parametric curves were fit for the DVRd and VRd groups. Extrapolations were capped by UK population data (2020–2022) on disease-specific and all-cause mortality, using median population age and the proportion of males in the cohort at treatment initiation. PFS projections begin at the median population age. In PERSEUS, 709 TE pts were randomized (DVRd, n=355; VRd, n=354; median age, 60 yrs; 59% male). In CEPHEUS, 289 TIE pts were randomized (DVRd, n=144; VRd, n=145; median age, 72 yrs; 51% male). At 48 mo, Kaplan-Meier estimates of PFS in PERSEUS TE pts were 84.3% vs 67.7% for DVRd and VRd, respectively; in CEPHEUS TIE pts, they were 72.3% vs 52.3% (Figure). Based on modeling in PERSEUS TE pts, estimated median PFS was 158–255 mo (13.2–21.2 yrs) for DVRd and 76–119 mo (6.3–9.9 yrs) for VRd. Exponential distribution (best fit) gave PFS estimates of 205 vs 87 mo (17.1 vs 7.3 yrs) for DVRd and VRd, respectively. In CEPHEUS TIE pts, estimated median PFS was 96–118 mo (8.0–9.8 yrs) for DVRd and 52–54 mo (4.3–4.5 yrs) for VRd. Exponential distribution gave PFS estimates of 100 vs 53 mo (8.3 vs 4.4 yrs) for DVRd and VRd, respectively. PFS projections were significantly longer with DVRd vs VRd in both TE and TIE pts with NDMM. As expected, projected PFS with DVRd was longer for TE (205 mo from baseline age of 60 yrs) vs TIE (100 mo from age 72 yrs). These extrapolations support DVRd use beyond observed PFS data, helping to reinforce the benefit of DVRd with daratumumab-containing maintenance in all pts with NDMM.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.009
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Simulation or modeling · Consensus signal: Simulation or modeling
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.053
Threshold uncertainty score0.106

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.009
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.145
GPT teacher head0.500
Teacher spread0.355 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSimulation or modeling
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueDOAJ (DOAJ: Directory of Open Access Journals)→Same topicMultiple Myeloma Research and Treatments→French-language works237,207→